January 02, 2026

Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable HCC

The expanded indication marks the first and only radioembolization therapy in the United States approved to treat both unresectable hepatocellular carcinoma (HCC) and colorectal cancer liver metastase...

The ASCO Post

January 02, 2026

Benefits Mount for TROP2-Directed Antibody-Drug Conjugates in Triple-Negative Breast Cancer

Two randomized phase III trials presented at the European Society for Medical Oncology (ESMO) Congress 2025 bolster support for the use of antibody–drug conjugates—in particular, trophoblast cell surf...

The ASCO Post

December 18, 2025

Can Prophylactic Radiation Prevent Complications of Bone Metastases in High-Risk, Asymptomatic Patients?

Some bone metastases appear to be at higher risk for such complications as pathologic fracture, spinal cord compression, pain or surgery to bone, even if they’re asymptomatic

Roswell Park Comprehensive Cancer Center

December 15, 2025

Phase III Trial Shows No Oncologic Benefit From Routine Preoperative MRI for Some Early Breast Cancers

Rates of local regional recurrence were very low for patients with early-stage triple-negative or HER2-positive breast cancer regardless of whether or not they received a breast MRI for staging and su...

The ASCO Post

December 12, 2025

Safety and Benefit of Radiation Therapy for High-Risk Muscle-Invasive Bladder Cancer

Following cystectomy, patients with muscle-invasive bladder cancer at high risk for recurrence may safely be treated with radiotherapy and may achieve an improvement in locoregional control compared w...

The ASCO Post

December 09, 2025

AI Tops Density in Predicting Breast Cancer Risk

An image-only artificial intelligence (AI) model for predicting the 5-year risk of breast cancer provided stronger and more precise risk stratification than breast density assessment, according to a n...

The ASCO Post

December 09, 2025

External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer

A machine learning–based survival model, incorporating preoperative CT images and routinely available clinical data, outperformed standard clinical staging systems in predicting recurrence after surge...

The ASCO Post

December 05, 2025

Long-Term Survival With Stereotactic Ablative Radiotherapy vs Surgery for Early-Stage NSCLC

With 10 years of follow-up, no significant difference in survival rates was reported between patients who were treated with stereotactic ablative radiotherapy (SABR) or video-assisted thoracoscopic su...

The ASCO Post

December 02, 2025

Preliminary Activity of LuPSMA-I&T Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis

In an interim analysis of an Australian single-center phase I/II trial (AlphaBet) reported in The Lancet Oncology, Kostos et al found that the combination of lutetium-177–labeled PSMA-I&T (LuPSMA-...

The ASCO Post